Angiotensin; Related Peptides Patents (Class 530/316)
-
Patent number: 5955430Abstract: Angiotensin II fragments and analogs thereof are useful in accelerating wound healing. These compounds form the basis of compositions useful for accelerating wound healing, in which the active agent is present in an amount effective to accelerate wound healing. Preferably, the compositions are in the form of matrical or micellar solutions.Type: GrantFiled: June 6, 1995Date of Patent: September 21, 1999Assignee: University of Southern CaliforniaInventors: Kathleen Elizabeth Rodgers, Gere Stodder diZerega
-
Patent number: 5843903Abstract: This invention is in the field of the chemistry of targeting anticancer anthracycline derivatives. More particularly, it concerns doxorubicin (DOX) or its daunosamine modified derivatives (DM-DOX) linked covalently to analogs of peptide hormones such as LH-RH, bombesin and somatostatin. These covalent conjugates are targeted to various tumors bearing receptors for the peptide hormone analogs. The compounds of this invention are represented by General Formula Q.sup.14 --O--R--P wherein Q has the general formula ##STR1## wherein: Q.sup.14 signifies a Q moiety with a side chain at the 14 position, R-- is H or --C(O)--(CH.sub.2).sub.n --C(O)-- and n=0-7, R' is NH.sub.2 or an aromatic, saturated or partially saturated 5 or 6 membered heterocyclic compounds having at least one ring nitrogen and optionally having a butadiene moiety bonded to adjacent carbon atoms of said ring to form a bicyclic system; P is H or a peptide moiety, suitably an LHRH, somatostatin or bombesin analogs. Nevertheless where R' is NH.sub.Type: GrantFiled: November 27, 1995Date of Patent: December 1, 1998Assignee: The Administrators of the Tulane Educational FundInventors: Andrew V. Schally, Attila A. Nagy, Ren-Zhi Cai
-
Patent number: 5834432Abstract: Angiotensin II Type 2 receptor agonists (AT2 receptor subtype agonists) are useful in accelerating wound healing. These compounds form the basis of compositions useful for accelerating wound healing, in which the active agent is present in an amount effective to accelerate wound healing. Preferably, the compositions are in the form of matrical or micellar solutions.Type: GrantFiled: June 6, 1995Date of Patent: November 10, 1998Assignee: The University of Southern CaliforniaInventors: Kathleen Elizabeth Rodgers, Gere Stodder Dizerega
-
Patent number: 5723307Abstract: Disclosed are new fluorogenic substrates for assay of angiotensin converting enzyme, a process for preparing them and methods for using them to assay angiotensin converting enzyme and to screen antihypertensive agents which inhibit angiotensin converting enzyme.Type: GrantFiled: August 30, 1995Date of Patent: March 3, 1998Assignee: Development Center for BiotechnologyInventors: Hsin Tsai, Hui-Ling Chen
-
Patent number: 5482925Abstract: Novel complexes of nitric oxide (NO) and amines are described where the amine is a known cardiovascular agent having at least one or more primary or secondary amino groups and whereby the resulting complex is capable under physiological conditions of releasing in vivo dual active ingredients, the NO and the known cardiovascular agent. The complexes are used for treating cardiovascular diseases and for the prophylactic or therapeutic treatment of restenosis.Type: GrantFiled: March 17, 1994Date of Patent: January 9, 1996Assignee: Comedicus IncorporatedInventor: Thomas C. Hutsell
-
Patent number: 5459077Abstract: Disclosed are methods for modelling the three-dimensional structure (tertiary structure) of a ligand having one or more active sites employing a charge-transfer interaction. Also disclosed is a model for Angiotensin II derived from such method.Type: GrantFiled: March 5, 1993Date of Patent: October 17, 1995Assignee: PepMetics, Inc.Inventors: Graham J. Moore, John M. Matsoukas
-
Patent number: 5369015Abstract: Disclosed is a method for producing an angiotensin converting enzyme inhibitor composition from natural materials, which composition is of use as an antihypertensive drug or diet. The method comprises heating a meat in water at a temperature not lower than 50.degree. C. to extract water-soluble protein and hydrolyzing the residue predominantly composed of water-insoluble protein with a protease.Type: GrantFiled: October 14, 1992Date of Patent: November 29, 1994Assignee: Nippon Gohsei Kagaku Kogyo Kabushiki KaishaInventors: Masaaki Yoshikawa, Keiichi Yokoyama, Masayasu Hasegawa, Ryouichi Yasumoto, Hiroyuki Fujita
-
Patent number: 5151502Abstract: A process for solubilizing membrane receptor proteins which includes exposing an outer membrane having the desired protein to an oxidizing agent, treating the membrane with a detergent and treating with an inhibitory material lowering agent. This method maintains the activity of the membrane proteins after solubilization.Type: GrantFiled: April 30, 1991Date of Patent: September 29, 1992Assignee: E. R. Squibb & Sons, Inc.Inventors: Maria L. Webb, Hossain Monshizadegan
-
Patent number: 5147857Abstract: New glycolic acid derivatives of the formula IX--O--CR.sup.1 R.sup.2 --CO--Y--NR.sup.3 --CHR.sup.4 --CR.sup.5 --CH.sub.2 --CR.sup.6 R.sup.7 --Z Iin which R.sup.1 to R.sup.7, X, Y and Z have the meanings indicated herein, and salts thereof, inhibit the activity of human plasma renin.Type: GrantFiled: March 18, 1991Date of Patent: September 15, 1992Assignee: Merck Patent Gesellschaft mit beschraenkter HaftungInventors: Peter Raddatz, Claus J. Schmitges, Klaus-Otto Minck
-
Patent number: 5015629Abstract: A method for increasing the rate of healing in mammalian tissue includes the administration of a solution of angiotensin II.Type: GrantFiled: March 9, 1990Date of Patent: May 14, 1991Assignee: University of Southern CaliforniaInventor: Gere S. diZerega
-
Patent number: 4966964Abstract: An inhibitor of angiogenin and method of use of the inhibitor, wherein the inhibitor inhibits the angiogenic activity of angiogenin. The inhibitor is dispensed at a suitable concentration within a physiologically compatable medium, suitable for administration to an animal in sufficient quantity to inhibit the biological activity of naturally occurring angiogenin within the animal.Type: GrantFiled: April 14, 1987Date of Patent: October 30, 1990Assignee: President and Fellows of Harvard CollegeInventors: Robert Shapiro, Bert L. Vallee
-
Patent number: 4911909Abstract: Monoclonal antibodies to angiotensin II and the continuous hybrid monoclonal cell lines for their production are provided. These antibodies are useful in the diagnosis and treatment of angiotensin II-induced hypertension.Type: GrantFiled: January 2, 1987Date of Patent: March 27, 1990Assignee: E. I. Du Pont De Nemours and CompanyInventor: Thomas M. Reilly
-
Patent number: 4897379Abstract: The invention relates to N-[N.sup..alpha. -(1(S)-carboxy-3-cyclohexylpropyl)-L-lysyl]-N-cyclopentylglycine which is useful as antihypertensives.Type: GrantFiled: March 24, 1988Date of Patent: January 30, 1990Assignee: Asahi Breweries Ltd.Inventors: Shizuo Saito, Motoshi Watanabe, Shuji Fukushima, Shinichi Matsui
-
Patent number: 4785080Abstract: A highly sensitive, immunoassay method for determining the amount of an analyte in a sample containing a known analyte in an unknown concentration is provided. Sample; a polypeptide-labeled analog of the analyte, an antibody specific for said analyte, a polypeptide partner capable of non-covalently binding with the polypeptide-labeled analyte to form a complex having catalytic activity, and a substrate capable of being converted to a reporter molecule by the catalytic activity of said complex are brought together in a medium. The polypeptide-labeled analyte analog is capable of competitively binding to the antibody and the polypeptide partner, the antibody inhibiting the formation of a catalytically active complex in the absence of analyte, and the concentration of the antibody, polypeptide partner and polypeptide-labeled analyte are such as to cause varying amounts of analyte to be directly related to the conversion of the substrate to the reporter molecule.Type: GrantFiled: August 29, 1985Date of Patent: November 15, 1988Assignee: Baker Instruments CorporationInventors: Peter R. Farina, James R. Golke
-
Patent number: 4772684Abstract: Peptides of the formula: ##STR1## wherein: NH is the .alpha. amino group of amino acid AA.sup.1 ; ##STR2## is the carbonyl group of amino acid AA.sup.7 ; X is H--, ##STR3## GLU-VAL-, or VAL-TYR-HIS-GLU-VAL; Y is --OH, --NH.sub.2, or --PRO; AA.sup.1 is LYS, GLU, GLN, pGLU, .beta.ALA, PRO, PRO-OH, PIC, or AIB; AA.sup.2 is VAL, LEU, ILE, MET, or AIB; AA.sup.3 is ASP, TYR, GLU, HIS, or PHE; AA.sup.4 is VAL, MET, ILE, LEU, or AIB; AA.sup.5 is TYR, HIS, or GLU; AA.sup.6 is ALA, PRO, SER, .beta.ALA, PRO-OH, or AIB; and AA.sup.7 is VAL, LEU, ILE, or AIB;and salts thereof are claimed as effective blood pressure regulators. Further provided, are antibodies to these peptides, as well as diagnostic and therapeutic methods for blood pressure regulation.Type: GrantFiled: February 18, 1988Date of Patent: September 20, 1988Assignee: Triton Biosciences, Inc.Inventors: Terence K. Brunck, Clarence Colby, Jr.
-
Patent number: 4672054Abstract: The invention relates to octapeptides of the formulaX-Arg-Val-Tyr-Y-His-Pro-W (I)whereinX is a sarcosyl, lactoyl or hydroxyacetyl radical,Y is cyclopentylglycyl or cyclohexylglycyl, andW is an alanine radical or lactic acid radicalhaving angiotensine-II antagonistic activity.Type: GrantFiled: August 1, 1985Date of Patent: June 9, 1987Assignee: Richter Gedeon Vegyeszeti Gyar Rt.Inventors: Olga Nyeki nee Kuprina, Lajos Kisfaludy, Katalin Szeberenyi nee Szalay, Gabor Makara, Bertalan Varga, Egon Karpati, Laszlo Szporny